Key result
Four weeks of insulin therapy decreased VLDL triglycerides and increased HDL2 mass in patients with noninsulin-dependent diabetes.
Why the study?
Does rigorous insulin therapy improve serum lipoproteins in patients with noninsulin-dependent diabetes not controlled with oral agents?
Does rigorous insulin therapy improve serum lipoproteins in patients with noninsulin-dependent diabetes not controlled with oral agents?
Intensive insulin therapy in noninsulin-dependent diabetes induces antiatherogenic changes in serum lipoproteins, likely driven by increased lipoprotein lipase activity.
Answers are grounded in this paper and cite their sources.
Supports antiatherogenic lipoprotein shifts with insulin in NIDDM; leaves open effects on clinical events.
To study the effects of rigorous insulin therapy on serum lipoproteins in patients with noninsulin-dependent diabetes not controlled with oral agents only, we measured serum lipoproteins, apoproteins, lipolytic enzymes, and glucose disposal using an insulin clamp technique before and after 4 weeks of insulin therapy. Lipoproteins were isolated by ultracentrifugation and high density lipoprotein (HDL) subfractions, by rate-zonal density gradient ultracentrifugation. The group included 11 women and eight men (age 58 +/- 1 years and RBW 125 +/- 4%). Body weight, glycosylated hemoglobin, mean diurnal glucose, plasma free insulin, and glucose uptake (M-value) were 75 vs. 76 kg; 11.9 vs. 8.9%; 234 vs. 124 mg/dl; 12 vs. 27 microU/ml; and 5.0 +/- 0.4 vs. 7.1 +/- 0.6 mg/kg/min before and after insulin therapy, respectively. After insulin therapy there was a decrease of very low density lipoprotein (VLDL) triglyceride (-60%, p less than 0.001) but an increase of HDL2 cholesterol (+21%, p less than 0.001); HDL2 phospholipids (+38%, p less than 0.001); HDL2 proteins (+23%, p less than 0.01); and HDL2 mass (127 +/- 11 vs. 158 +/- 12 mg/dl, p less than 0.001). There was a decrease of HDL3 cholesterol (-13%, p less than 0.05); HDL3 phospholipids (-16%, p less than 0.05); HDL3 proteins (-18%, p less than 0.001); and HDL3 mass (179 +/- 6 vs. 146 +/- 6, p less than 0.01). Zonal profiles showed a redistribution of particles from HDL3 to HDL2. Serum apo A-I increased (p less than 0.05), apo A-II remained constant, but apo B decreased (-29%, p less than 0.001). The most marked change during insulin therapy was a 2.3-fold increase in adipose tissue lipoprotein lipase (LPL) activity (p less than 0.001). The changes of VLDL and HDL subfractions were not explained by respective changes of the blood glucose, free insulin, or M-value. The data indicate that intensive insulin therapy induces antiatherogenic changes in serum lipids and lipoproteins and suggest that the induction of LPL by insulin is the major factor responsible for redistribution of HDL particles from HDL3 to HDL2.
No takes yet. Share an insight, caveat, or question.
Taskinen et al. (1988) studied Noninsulin-dependent diabetes (n=19). Insulin therapy vs. Baseline (before insulin therapy) was evaluated on HDL2 mass (mg/dl) (p=<0.001). Four weeks of insulin therapy decreased VLDL triglycerides and increased HDL2 mass in patients with noninsulin-dependent diabetes.
Synapse has enriched 10 related papers. Consider them for comparative context: